Sorrento Therapeutics Inc. (SRNE.OB) Announces Collaborative Development Agreement with Scripps Research
Sorrento Therapeutics Inc. is a development-stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of disease conditions such as cancer, inflammation, metabolic disease and infectious disease. The company today announced it has entered into an antibody discovery and development collaboration with The Scripps Research Institute in La Jolla, Calif. Per the agreement, Sorrento will obtain exclusive, worldwide rights to Scripps Research’s novel quorum sensing-based technology, which was developed to prevent and treat Staphylococcus aureus (commonly known as Staph) infections, including Methicillin-resistant Staph. aureus (MRSA). MRSA’s resistance to antibiotics makes it a concern to healthcare officials. According to the…